.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,883,794

« Back to Dashboard

Claims for Patent: 8,883,794

Title:Pharmaceutical composition
Abstract: A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethyle- ne-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]-heptanedicarboxylmide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
Inventor(s): Fujihara; Kazuyuki (Suzuka, JP)
Assignee: Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)
Application Number:14/183,283
Patent Claims: 1. An oral preparation comprising 20 to 120 mg of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethyle- ne-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1]heptanedicarboxylmide hydrochloride (lurasidone) of formula (1): ##STR00003## a pregelatinized starch, a water-soluble excipient, a water-soluble polymer binder, a disintegrant, and a lubricant, wherein the content of lurasidone in the preparation is 20 to 45% (wt/wt), and the content of the pregelatinized starch in the preparation is 20 to 30% (wt/wt).

2. The oral preparation of claim 1, wherein the water-soluble excipient is mannitol or lactose, and the content of water-soluble excipient in the preparation is 40 to 60% (wt/wt).

3. The oral preparation of claim 2, wherein the water-soluble excipient is mannitol.

4. The oral preparation of claim 3, wherein the water-soluble binder is hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidine or hydroxypropylcellulose, and the content of water-soluble binder in the preparation is 1 to 5% (wt/wt).

5. The oral preparation of claim 4, wherein the water-soluble binder is hydroxypropyl methylcellulose.

6. The oral preparation of claim 5, wherein the disintegrant is corn starch, crystalline cellulose, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium, or crospovidone, and the content of the disintegrant in the preparation is 0.5 to 5% (wt/wt).

7. The oral preparation of claim 6, wherein the disintegrant is croscarmellose sodium.

8. The oral preparation of claim 7, wherein the lubricant is magnesium stearate, talc, polyethylene glycol, silica or hydrogenated vegetable oil, and content of the lubricant in the preparation is 1.0 to 1.43% (wt/wt).

9. The oral preparation of claim 8, wherein the lubricant is magnesium stearate.

10. The oral preparation of claim 9, wherein the content of lurasidone is 20 mg.

11. The oral preparation of claim 9, wherein the content of lurasidone is 40 mg.

12. The oral preparation of claim 9, wherein the content of lurasidone is 80 mg.

13. The oral preparation of claim 9, wherein the content of lurasidone is 120 mg.

14. The oral preparation of claim 1, wherein the oral preparation is a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc